A critical re-evaluation of Mohs micrographic surgery for a facial basal cell carcinoma in older adults: should we waive this treatment in certain patients?

Clinicians should assess the aCCI in older patients presenting with a facial BCC before deciding if MMS is an eligible treatment option. High aCCI has shown to be an indicator for low median survival, even in MMS patients with usually high functional status. MMS should be waived as treatment in older patients with high aCCI scores in favor of other, less intensive and less expensive treatment options.